Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Rectal Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Endometrial Neoplasms 1Anus Neoplasms 1

Interventions

Abiraterone Acetate 7enzalutamide 6olaparib 5Prednisone 5Pluvicto 5Docetaxel 5radium Ra 223 dichloride 4darolutamide 4cabazitaxel 3Prednisolone 3testosterone 17 beta-cypionate 2fludarabine 2abiraterone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1niraparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × alovudine × Genitourinary × Clear all
NCT07609225 2026-05-27

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

University of Wisconsin, Madison

Phase EARLY_PHASE1 Not yet recruiting
15 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡